Higher-Dose eye shot aims to cut down treatment visits for common vision loss
NCT ID NCT07423429
Summary
This study is looking back at medical records to see if switching patients with a severe form of wet age-related macular degeneration (AMD) to a new, higher-dose version of an existing eye injection (aflibercept 8 mg) helps. The main goal is to see if patients can go longer between injections while still controlling the disease and preserving vision. It will involve about 100 adults in France who were already receiving regular eye injections but needed them too frequently.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXUDATIVE AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.